

## 11TH ANNUAL MEETING OF THE LUPUS ACADEMY

Pre-Meeting Session: 25<sup>th</sup> March 2022

Hybrid Meeting: 8–10<sup>th</sup> April 2022

Catch-up Content available Online until 30<sup>th</sup> June 2022

[www.lupus-academy.org](http://www.lupus-academy.org)

### LUPUS ACADEMY 11TH ANNUAL MEETING

FRIDAY 25<sup>TH</sup> MARCH 2022

#### PRE-MEETING SESSION I: OLD DRUGS ON THE STAGE

(LIVE-STREAMED)

CET (UTC +1 Rome) 14:00 – 16:00 hours

PST (UTC +8 Manila) 21:00 – 23:00 hours

EDT (UTC -4 New York) 9:00 AM – 11:00 AM

<i>Moderators: Zahir Amoura (France) &amp; Thomas Dörner (Germany)</i>		
14:00	Glucocorticoids for SLE: What are the current questions and issues? <i>Q&amp;A and Discussion (15 Mins)</i>	<i>Guillermo Ruiz-Irastorza (Spain)</i>
14:30	Cyclophosphamide: What is its role in the treatment of lupus nephritis and the new treatment paradigm? <i>Q&amp;A and Discussion (15 Mins)</i>	<i>Liz Lightstone (UK)</i>
15:00	Top 10 tips regarding patient adherence to hydroxychloroquine <i>Q&amp;A and Discussion (15 Mins)</i>	<i>Nathalie Costedoat-Chalumeau (France)</i>
15:30	Panel Discussion (30 Mins)	<i>All</i>
16:00	Close	

**LUPUS ACADEMY 11TH ANNUAL MEETING  
FRIDAY 8<sup>TH</sup> APRIL 2022**

**OPENING SESSION  
(LIVE-STREAMED)**

**CEST (UTC +2 Rome) 13:30–15:45 hours**

**PST (UTC +8 Manila) 19:30 – 21:30 hours**

**EDT (UTC -4 New York) 7:30 AM – 9:45 AM**

<b>Moderators: Eloisa Bonfá (Brazil) &amp; Ronald van Vollenhoven (Netherlands)</b>		
<b>13:30</b>	<b>Opening Address</b>	<i>Andrea Doria (Italy) &amp; Eloisa Bonfá (Brazil)</i>
	<b>Debate</b>	
<b>13:35</b>	The matter of the debate: LLDAS is an excellent outcome measure, but does it really capture patients with true LDA? <i>(10 Mins)</i>	<i>Ronald van Vollenhoven (Netherlands)</i>
	YES <i>(20 Mins + 10 Mins Rebuttal)</i>	<i>Eric Morand (Australia)</i>
	NO <i>(20 Mins + 10 Mins Rebuttal)</i>	<i>Andrea Doria (Italy)</i>
	Voting, Q&A and Discussion (20 Mins)	All
<b>Moderators: Andrea Doria (Italy) &amp; Eloisa Bonfá (Brazil)</b>		
	<b>Keynote</b>	
<b>15:05</b>	B cells as a therapeutic target in SLE: Where we are today and where we may be tomorrow <i>Q&amp;A and Discussion (15 Mins)</i>	<i>Thomas Dörner (Germany)</i>
<b>15:45</b>	<b>Break</b>	

**PLENARY I: CONTROVERSIAL ISSUES IN THE MANAGEMENT OF SLE  
CEST (Paris, Amsterdam, Berlin) UTC +2: 16:15–18:15**

<b>Moderators: Andrea Doria (Italy) &amp; Eloisa Bonfá (Brazil)</b>		
<b>16:15</b>	Are DOACs dead? Or do they still have a role in SLE/APS? <i>Q&amp;A and Discussion (15 Mins)</i>	<i>David Isenberg (UK)</i>
<b>16:45</b>	COVID-19 vaccine in lupus patients <i>Q&amp;A and Discussion (15 Mins)</i>	<i>Eloisa Bonfá (Brazil)</i>
<b>17:15</b>	Novel concepts in SLE: Is it time for a new taxonomy? <i>Q&amp;A and Discussion (15 Mins)</i>	<i>Ronald van Vollenhoven (Netherlands)</i>
<b>17:45</b>	Should PROs be incorporated in the response evaluation? <i>Q&amp;A and Discussion (15 Mins)</i>	<i>Marta Mosca (Italy)</i>
<b>18:15</b>	<b>Close Followed by Evening Networking</b>	

## LUPUS ACADEMY 11<sup>TH</sup> ANNUAL MEETING

SATURDAY 9<sup>TH</sup> APRIL 2022

### CASE STUDY INTERACTIVE WORKSHOPS

CEST (Paris, Amsterdam, Berlin) UTC +2: 09:00–10:30

<b>Moderator: David Isenberg (UK)</b>		
09:00	Management of lupus skin manifestations	Annegret Kuhn (Germany) & Marzia Caproni (Italy)
<b>Moderator: Andrea Doria (Italy)</b>		
09:00	Management of lupus nephritis	Gabriella Moroni (Italy) & Richard Furie (USA)
<b>Moderator: Murray Urowitz (Canada)</b>		
09:00	Management of neuropsychiatric SLE	Dimitrios Boumpas (Greece) & Zahir Amoura (France)
<b>Moderator: Thomas Dörner (Germany)</b>		
09:00	Management of pregnancy in SLE and APS	Angela Tincani (Italy) & Jill Buyon (USA)
10:30	Break	

### THIEVES' MARKET

CEST (Paris, Amsterdam, Berlin) UTC +2: 11:00–12:00

<b>Moderators: Zahir Amoura (France) &amp; Eloisa Bonfá (Brazil)</b>		
11:00	Case in practice: Diaries from a long journey Q&A and Discussion (10 Mins)	Edoardo Marrani (Italy)
11:15	Case in practice: I'm becoming "Michelin Man" progressively Q&A and Discussion (10 Mins)	Carolina Aulestia (Ecuador)
11:30	Case in practice: When your mouth pops Q&A and Discussion (10 Mins)	Francisca Guimarães (Portugal)
11:45	Discussion and Awards	
12:00	Lunch	

### PRIME TIME SESSION: TREATMENT TARGETS AND NOVEL THERAPIES (LIVE-STREAMED)

CEST (UTC +2 Rome): 13:15–15:45 hours

PST (UTC +8 Manila) 19:15 – 21:45 hours

EDT (UTC -4 New York) 7:15 AM – 9:45 AM

<b>Moderators: Zahir Amoura (France) &amp; Murray Urowitz (Canada)</b>		
13:15	Cells involved in SLE: Beyond B cells Q&A and Discussion (15 Mins)	Anne Davidson (USA)
13:45	Cytokines involved in SLE: Beyond IFN Q&A and Discussion (15 Mins)	George Tsokos (USA)
14:15	New and approved therapies for SLE: Anifrolumab Q&A and Discussion (15 Mins)	Ronald van Vollenhoven (Netherlands)
14:45	New and approved therapies for LN: Belimumab and voclosporin Q&A and Discussion (15 Mins)	Richard Furie (USA)
15:15	Panel Discussion (30 Mins)	
15:45	Break	

## CASE STUDY INTERACTIVE WORKSHOPS

**CEST (Paris, Amsterdam, Berlin) UTC +2: 16:15–17:45**

<i>Moderator: David Isenberg (UK)</i>		
16:15	Management of lupus skin manifestations	<i>Annegret Kuhn (Germany) &amp; Marzia Caproni (Italy)</i>
<i>Moderator: Andrea Doria (Italy)</i>		
16:15	Management of lupus nephritis	<i>Gabriella Moroni (Italy) &amp; Richard Furie (USA)</i>
<i>Moderator: Murray Urowitz (Canada)</i>		
16:15	Management of neuropsychiatric SLE	<i>Dimitrios Boumpas (Greece) &amp; Zahir Amoura (France)</i>
<i>Moderator: Thomas Dörner (Germany)</i>		
16:15	Management of pregnancy in SLE and APS	<i>Angela Tincani (Italy) &amp; Jill Buyon (USA)</i>
17:45	Close	

## LUPUS ACADEMY 11<sup>TH</sup> ANNUAL MEETING

**SUNDAY 10<sup>TH</sup> APRIL 2022**

### PLENARY II: CHALLENGES IN LUPUS

**CEST (Paris, Amsterdam, Berlin) UTC +2: 08:30–10:30**

<i>Moderators: Eloisa Bonfá (Brazil) &amp; David Isenberg (UK)</i>		
08:30	Disease activity and treatment targets in SLE <i>Q&amp;A and Discussion (10 Mins)</i>	<i>Luís Ines (Portugal)</i>
08:55	Molecular signatures in kidney biopsies and their relationship to clinical activity <i>Q&amp;A and Discussion (10 Mins)</i>	<i>Jill Buyon (USA)</i>
09:20	What drives rapid progression to ESRD in patients with lupus nephritis? <i>Q&amp;A and Discussion (10 Mins)</i>	<i>Murray Urowitz (Canada)</i>
09:45	Increased CV risk in women with SLE: Stories from a panel of biomarkers <i>Q&amp;A and Discussion (10 Mins)</i>	<i>Matteo Piga (Italy)</i>
10:10	Panel Discussion (20 Mins)	
10:30	Break	

### POSTER SESSION: PRESENTATIONS

**CEST (PARIS, AMSTERDAM, BERLIN) UTC +2: 11:00–12:00**

<i>Moderators: Andrea Doria (Italy) &amp; Eloisa Bonfá (Brazil)</i>		
11:00	Adaptation and validation of the Systemic Lupus Erythematosus Quality of Life Questionnaire (L-QoL) for use in Bulgaria <i>Q&amp;A (5 Mins)</i>	<i>Daliya Tsvetanova Pencheva (Bulgaria)</i>
11:10	Relationship of anti-double stranded DNA antibodies titers and echocardiographic parameters in systemic lupus erythematosus patients <i>Q&amp;A (5 Mins)</i>	<i>Natalia Guajardo-Jauregui (Mexico) &amp; Iris Colunga-Pedraza (Mexico)</i>
11:20	Patients with SLE have unique changes in serum metabolic profiles across age associated with cardiometabolic risk	<i>George A Robinson (UK)</i>

	Q&A (5 Mins)	
11:30	Intercurrent infection as a risk factor for disease flares in patients with systemic lupus erythematosus	<i>Fatma el Hadiyen (The Netherlands)</i>
11:40	Transcriptome profiling and autoimmunity-related serological markers identify TP53 and C3aR as drug targets in neuropsychiatric systemic lupus erythematosus Q&A (5 Mins)	<i>Julius Lindblom (Sweden)</i>
11:50	Discussion and Award (10 Mins)	<i>All</i>
12:00	<b>Poster Viewing and Light Lunch</b>	

\*More Posters Available at [lupus-academy.org](http://lupus-academy.org)

### PLENARY III: DIFFICULT-TO-TREAT LUPUS (LIVE-STREAMED)

CEST (UTC +2 Rome): 13:00–15:00 hours

PST (UTC +8 Manila) 19:00 – 21:00 hours

EDT (UTC -4 New York) 7:00 AM – 9:00 AM

<b>Moderators: Murray Urowitz (Canada) &amp; Andrea Doria (Italy)</b>		
13:00	APS antibodies: Managing patients when laboratory scenarios don't fit guidelines Q&A and Discussion (15 Mins)	<i>Ricard Cervera (Spain)</i>
13:30	Cardiovascular disease burden in SLE: Risk assessment and management Q&A and Discussion (15 Mins)	<i>Maria Tektonidou (Greece)</i>
14:00	Fatigue in SLE Q&A and Discussion (15 Mins)	<i>Laurent Arnaud (France)</i>
14:30	Infections in SLE Q&A and Discussion (15 Mins)	<i>Sandra Navarra (Philippines)</i>
15:00	<b>Meeting Close</b>	<i>Andrea Doria (Italy) &amp; Eloisa Bonfá (Brazil)</i>